NILO THERAPEUTICS LAUNCHES WITH $101 MILLION SERIES A FINANCING TO ADVANCE A NEW CLASS OF MEDICINES TARGETING NEURAL CIRCUITS IN IMMUNE DISEASE AND APPOINTS KIM SETH AS CHIEF EXECUTIVE OFFICER

NEW YORK, Oct 9 (Bernama) -- Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by The Column Group (TCG), DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. Coinciding with its launch, Nilo announced the appointment of Kim Seth, Ph.D., as Chief Executive Officer and Board director.

Founded by world-leading scientists Charles Zuker, Ph.D. (Columbia University), Ruslan Medzhitov, Ph.D. (Yale University), and Steve Liberles, Ph.D. (Harvard University), Nilo was created in collaboration with TCG to translate groundbreaking scientific insights in neuro-immunology into new therapeutic strategies. Dr. Seth joins Chief Scientific Officer Laurens Kruidenier, Ph.D., in leading the company’s transition from stealth into its next stage of growth. The financing fuels the establishment of Nilo’s laboratories in New York City, growth of its interdisciplinary research and development team, and advancement of the company’s preclinical programs.